Indefinite-Lived Research and Development Assets
Cardinal Health Indefinite-Lived Research and Development Assets increased by 78.6% to $25.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 92.3%, from $13.00M to $25.00M. Over 4 years (FY 2021 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 2.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assetsHistorical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.00M | $12.00M | $12.00M | $13.00M | $11.00M | $11.00M | $11.00M | $11.00M | $11.00M | $12.00M | $12.00M | $11.00M | $12.00M | $12.00M | $12.00M | $13.00M | $13.00M | $14.00M | $14.00M | $25.00M |
| QoQ Change | — | +0.0% | +0.0% | +8.3% | -15.4% | +0.0% | +0.0% | +0.0% | +0.0% | +9.1% | +0.0% | -8.3% | +9.1% | +0.0% | +0.0% | +8.3% | +0.0% | +7.7% | +0.0% | +78.6% |
| YoY Change | — | — | — | — | -8.3% | -8.3% | -8.3% | -15.4% | +0.0% | +9.1% | +9.1% | +0.0% | +9.1% | +0.0% | +0.0% | +18.2% | +8.3% | +16.7% | +16.7% | +92.3% |
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Cardinal Health's indefinite-lived research and development assets?
- Cardinal Health (CAH) reported indefinite-lived research and development assets of $25.00M in Q1 2026.
- How has Cardinal Health's indefinite-lived research and development assets changed year-over-year?
- Cardinal Health's indefinite-lived research and development assets increased by 92.3% year-over-year, from $13.00M to $25.00M.
- What is the long-term trend for Cardinal Health's indefinite-lived research and development assets?
- Over 4 years (2021 to 2025), Cardinal Health's indefinite-lived research and development assets has grown at a 2.0% compound annual growth rate (CAGR), from $12.00M to $13.00M.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.